Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data

PURPOSE: Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known about patie...

Descripción completa

Detalles Bibliográficos
Autores principales: den Hollander, Dide, Dirkson, Anne R., Verberne, Suzan, Kraaij, Wessel, van Oortmerssen, Gerard, Gelderblom, Hans, Oosten, Astrid, Reyners, Anna K. L., Steeghs, Neeltje, van der Graaf, Winette T. A., Desar, Ingrid M. E., Husson, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046353/
https://www.ncbi.nlm.nih.gov/pubmed/35233640
http://dx.doi.org/10.1007/s00520-022-06929-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046353/
https://www.ncbi.nlm.nih.gov/pubmed/35233640
http://dx.doi.org/10.1007/s00520-022-06929-3

Ejemplares similares